Literature DB >> 14532781

The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.

M M Cherrier1, A L Rose, C Higano.   

Abstract

PURPOSE: Men with prostate specific antigen (PSA) only relapse of prostate cancer after primary therapy are generally fully functional and asymptomatic with a life expectancy of up to 10 or more years. These patients are often treated with androgen suppression. We evaluate the effects of androgen suppression on cognitive function.
MATERIALS AND METHODS: Hormone naïve patients without evidence of metastases with an increasing PSA were treated with intermittent androgen suppression consisting of 9 months of leuprolide and flutamide followed by an off treatment period determined by the increase in PSA. Cognitive function tests were administered at baseline, after 9 months of androgen suppression and after 3 months off treatment. Cognitive tests measured spatial abilities, spatial memory, verbal fluency, verbal memory and selective attention. A total of 19 patients 52 to 76 years old completed the intermittent androgen suppression study along with 15 healthy community dwelling control participants.
RESULTS: Combined androgen blockade reduced PSA and testosterone in all patients compared to baseline. Patients did not significantly change on measures of verbal and spatial memory, executive functions or language. Patients declined on a measure of spatial rotation and improved on a measure of verbal memory during treatment which continued during the off treatment period.
CONCLUSIONS: Although preliminary, these findings demonstrate that 9 months of combined androgen blockade resulted in a beneficial effect on verbal memory but adversely affected a measure of spatial ability. Intermittent androgen suppression for a period of 9 months in otherwise healthy men with prostate cancer may have beneficial and adverse effects on cognition that are selective.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14532781     DOI: 10.1097/01.ju.0000091640.59812.83

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  35 in total

Review 1.  Cognitive changes associated with ADT: a review of the literature.

Authors:  Rhoda J Jamadar; Mary J Winters; Pauline M Maki
Journal:  Asian J Androl       Date:  2012-02-20       Impact factor: 3.285

2.  Cardiac and cognitive effects of androgen deprivation therapy: are they real?

Authors:  S M H Alibhai; H Z Mohamedali
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

3.  Sex differences in visuospatial abilities persist during induced hypogonadism.

Authors:  Gioia M Guerrieri; Paul G Wakim; P A Keenan; Linda A Schenkel; Kate Berlin; Carolyn J Gibson; David R Rubinow; Peter J Schmidt
Journal:  Neuropsychologia       Date:  2015-12-21       Impact factor: 3.139

Review 4.  Memory and cancer: a review of the literature.

Authors:  Graham J McDougall; JoAnn S Oliver; Forrest Scogin
Journal:  Arch Psychiatr Nurs       Date:  2014-03-22       Impact factor: 2.218

Review 5.  Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis.

Authors:  Heather L McGinty; Kristin M Phillips; Heather S L Jim; Julie M Cessna; Yasmin Asvat; Mallory G Cases; Brent J Small; Paul B Jacobsen
Journal:  Support Care Cancer       Date:  2014-05-25       Impact factor: 3.603

Review 6.  What are critical outcome measures for patients receiving pituitary replacement following brain injury?

Authors:  Sorin G Beca; Walter M High; Brent E Masel; Kurt A Mossberg; Randall J Urban
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

Review 7.  Androgens and male aging: Current evidence of safety and efficacy.

Authors:  Louis J Gooren
Journal:  Asian J Androl       Date:  2010-02-15       Impact factor: 3.285

Review 8.  Management of complications of androgen deprivation therapy in the older man.

Authors:  Supriya G Mohile; Karen Mustian; Kathryn Bylow; William Hall; William Dale
Journal:  Crit Rev Oncol Hematol       Date:  2008-10-25       Impact factor: 6.312

Review 9.  Cognitive effects of hormone therapy in men with prostate cancer: a review.

Authors:  Christian J Nelson; Jennifer S Lee; Maria C Gamboa; Andrew J Roth
Journal:  Cancer       Date:  2008-09-01       Impact factor: 6.860

10.  Gonadectomy and hormone replacement exert region- and enzyme isoform-specific effects on monoamine oxidase and catechol-O-methyltransferase activity in prefrontal cortex and neostriatum of adult male rats.

Authors:  B Meyers; A D'Agostino; J Walker; M F Kritzer
Journal:  Neuroscience       Date:  2009-11-10       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.